Sev­er­al weeks af­ter get­ting hit with an RTF, Y-mAbs lands ap­proval for its oth­er neu­rob­las­toma can­di­date

Near­ly two months af­ter hand­ing Y-mAbs a re­fusal to file let­ter for one of its main neu­rob­las­toma can­di­dates, the FDA gave the biotech an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA